SALT LAKE CITY, Jan. 4, 2024 /PRNewswire/ — DiscGenics, Inc., a privately held, late-stage medical, biopharmaceutical firm creating allogeneic, cell-based, regenerative therapies for musculoskeletal degeneration, at present introduced that Flagg Flanagan, Chief Government Officer and Chairman of DiscGenics is presenting at Biotech Showcase 2024.
- Date: Wednesday, January 10, 2024
- Time: 2:45 PM PST
- Observe: Franciscan A (Ballroom Stage)
Flanagan will current an replace on DiscGenics’ lead product candidate, IDCT (injectable disc cell remedy, or rebonuputemcel), a standalone, single-injection biologic therapy designed to halt development of lumbar disc degeneration and regenerate the disc from the within out. He will even present a quick overview of the Firm’s pre-clinical growth of a follow-on allogeneic cell platform and a complete biologic disc substitute in growth with the U.S. Division of Veterans Affairs.
Biotech Showcase is an investor and networking convention centered on driving advances in therapeutic growth. Now in its 16th 12 months, the convention takes place yearly in San Francisco throughout one of many business’s largest gatherings and busiest weeks.
“We’re delighted that DiscGenics will likely be becoming a member of us in San Francisco and presenting at Biotech Showcase this 12 months,” mentioned Sara Demy, CEO of Demy-Colton. “Biotech Showcase is a primary alternative for all times science entrepreneurs and traders to return collectively to find the potential of revolutionary applied sciences that may drive the way forward for drug discovery.”
Registered attendees can view DiscGenics’ presentation reside and on-demand.
About DiscGenics
DiscGenics is a privately held, late-stage medical biopharmaceutical firm creating allogeneic, cell-based regenerative therapies for musculoskeletal degeneration. It’s lead product candidate, IDCT (injectable disc cell remedy, or rebonuputemcel), is a standalone, single-injection biologic therapy designed to halt development of lumbar disc degeneration and regenerate the disc from the within out. IDCT is coming into pivotal Section III trials within the U.S. to focus on ache and incapacity in sufferers with lumbar disc degeneration. The lively ingredient in IDCT is a reside, manufactured progenitor cell inhabitants derived from donated grownup human intervertebral disc tissue, blended with a viscous provider. IDCT has been granted regenerative drugs superior remedy (RMAT) and Quick Observe designations by the U.S. Food and Drug Administration. DiscGenics can also be creating a follow-on allogeneic cell platform to allow new musculoskeletal indications. To additional growth of those distinctive therapies, and to keep up management over compliance, price, and manufacturing timelines, DiscGenics has constructed and validated an in-house scalable, allogeneic cell manufacturing course of and cGMP facility at its headquarters in Salt Lake Metropolis, Utah. For extra info, go to discgenics.com.
SOURCE DISCGENICS, INC.
Discussion about this post